IL17A and asthma: Brodalumab, a humanized mAb that binds to IL-17RA, thereby blocking the receptor and the downstream signal pathways of IL-17A, IL-17F, and other IL-17 isoforms, also did not achieve improvement in patients who were taking ICS and had inadequately controlled moderate-to-severe asthma [36].